Association between Serum Galectin-3 and Growth Differentiation Factor-15 Levels and Coronary Slow Flow Phenomenon

Basit Öğe Kaydı
dc.authorwosidYildiz, Cennet/HQY-3314-2023
dc.authorwosidyuksel, yasin/HPB-8683-2023
dc.contributor.authorYuksel, Yasin
dc.contributor.authorYildiz, Cennet
dc.contributor.authorBulut, Huri
dc.date.accessioned2024-05-19T14:40:28Z
dc.date.available2024-05-19T14:40:28Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground: Coronary slow flow phenomenon (CSFP) is characterized by delay in the progression of contrast material in the coronary tree that is not accompanied by significant coronary artery narrowing. Pathophysiologic pathways underpinning CSFP still remain poorly understood. Objectives: To evaluate the relationship between serum galectin-3 (GAL-3) and growth differentiation factor-15 Methods: Fifty CSFP patients and 40 subjects with normal coronary arteries were included in this retrospective study. The patients' serum GDF-15 and GAL-3 concentration levels were measured using relevant kits. Thrombolysis in myocardial infarction frame count (TFC) of each patients was determined. Results: We did not find any differences with respect to clinical and demographic features between the two groups. GDF-15 and GAL-3 concentration levels were significantly higher in the patients with CSFP. Moreover GDF-15 and GAL-3 concentration levels were positively correlated with TFC (GDF-15; r = 0.448, GAL-3; r = 0.642, p < 0.001 for both). Multivariate logistic regression showed that GAL-3 and GDF-15 were predictors of the CSFP. Similarly, GDF15 and GAL-3 were the only predictors of TFC. More specifically, GDF-15 and GAL-3 concentration levels of 182.18 pg/mL and 8.58 ng/mL predicted CSFP with sensitivities of 76% and 87.5%, respectively, and specificities of 84% and 75%, respectively. Conclusions: GDF-15 and GAL-3 levels were increased in the CSFP patients and predicted the presence and severity of CSFP. Thus, these two biomarkers might prove useful in relation to the diagnosis of CSFP.en_US
dc.identifier.doi10.6515/ACS.202307_39(4).20221128A
dc.identifier.endpage579en_US
dc.identifier.issn1011-6842
dc.identifier.issue4en_US
dc.identifier.pmid37456936en_US
dc.identifier.scopus2-s2.0-85166734729en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage572en_US
dc.identifier.urihttps://doi.org10.6515/ACS.202307_39(4).20221128A
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4965
dc.identifier.volume39en_US
dc.identifier.wosWOS:001030257100005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaiwan Soc Cardiologyen_US
dc.relation.ispartofActa Cardiologica Sinicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCoronary Slow Flowen_US
dc.subjectGalectin-3en_US
dc.subjectGrowth Differentiation Factor-15en_US
dc.subjectInflammationen_US
dc.titleAssociation between Serum Galectin-3 and Growth Differentiation Factor-15 Levels and Coronary Slow Flow Phenomenonen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu